Yair E.

Medical Doctor , Partner Deloitte UK Ex‑McKinsey, Bain & Private Equity Healthcare & Life Sciences Leader Board & Interim Exec

📍 United Kingdom🔄 Updated October 2026💼 5 investments📅 4 years investing🗓 Last invested Jan 2024
VC🌍 United Kingdom
5
Total investments
0
Early stage
0
Mid stage
2
Late stage
4y
Years active

Portfolio

3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Jan 2024
We are practitioners with centuries of combined expertise in enhancing organizations with innovative, human-centric solutions that create substantial and sustainable value by improving efficiency and profitability through intelligent technologies. We stand out because of our unique way of doing things.   Our Holistic Approach: We use smart technology to improve your current systems, processes, and people so that everything runs smoother.   People-Centric: We dont just focus on tech; we blend our expertise with empathy. We care about your long-term success and ensure you get real value from our services.  Trusted Partners: Were not your typical consultants. We genuinely care about your success . We build strong partnerships with your team, respecting their time and valuing their experience.  Talk to us about how we can help you accelerate or kick off your human-tech powered journey.
Board Member
Nov 2022
Founded in 2015, LXO Group is a pharmaceutical company operating a range of products generating annual sales of over 90 million euros and covering more than 80 countries. We are committed to meeting the needs of healthcare professionals and patients for our medicines, medical devices and cosmetics. Our growth is fuelled by the success of our brands, our international expansion and our strategy of external acquisitions. We are supported by a strong workforce, our own sales force and a network of partners and sales representatives who are ready to invest in the development of our products.
Board Member
Jun 2022
Virax Biolabs is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases.
Experience · 9 entries
All (9)
Investments (5)
Board (5)
2025
Partner
Aug 2025
Deloitte drives progress. Our firms around the world help clients become leaders wherever they choose to compete. Deloitte invests in outstanding people of diverse talents and backgrounds and empowers them to achieve more than they could elsewhere. Our work combines advice with action and integrity. We believe that when our clients and society are stronger, so are we. Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities. DTTL (also referred to as “Deloitte Global”) and each of its member firms are legally separate and independent entities. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more. The content on this page contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the “Deloitte Network”) is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on content from this page.
2024
Board Member
Jan 2024
We are practitioners with centuries of combined expertise in enhancing organizations with innovative, human-centric solutions that create substantial and sustainable value by improving efficiency and profitability through intelligent technologies. We stand out because of our unique way of doing things.   Our Holistic Approach: We use smart technology to improve your current systems, processes, and people so that everything runs smoother.   People-Centric: We dont just focus on tech; we blend our expertise with empathy. We care about your long-term success and ensure you get real value from our services.  Trusted Partners: Were not your typical consultants. We genuinely care about your success . We build strong partnerships with your team, respecting their time and valuing their experience.  Talk to us about how we can help you accelerate or kick off your human-tech powered journey.
2023
Board Member
May 2023
MyMeds&Me, a Qinecsa Solutions company, provides an end-to-end pharmacovigilance solution to simplify adverse event and product quality data capture and accelerate safety insights. Founded in 2012 by Senior Pharma executives with direct experience of managing pharmacovigilance systems, MyMeds&Me’s goal is to accelerate safety insights through digital transformation. The Reportum platform is a proven, scalable drug safety platform for the capture, management & processing of adverse events & product quality complaints. Learn more at: mymedsandme.com
Board Member
Jan 2023
We are Qinecsa. Trusted partners to global life science companies. We bring together comprehensive safety technology products and scientific expertise to connect life science companies to the right safety solutions. Through our unique insight into the challenges of pharmacovigilance, we have created industry-leading, end-to-end solutions for capturing, managing, and evaluating drug safety data, more efficiently and accurately. We pride ourselves on offering industry-leading pharmacovigilance technology products to support the pharmacovigilance landscape of tomorrow unlocking the power of end-to-end solutions: Reportum platform Our automated case intake and follow up platform, Reportum, provides a centralized solution for multi-lingual data capture across all intake sources to increase efficiencies and standardize safety data intake and management. HALOPV Revolutionary platform for managing all drug safety processes comprehensively, from ICSR, submissions, Aggregates, signal, risk management, PSMF, and beyond. Vigilance Workbench (CVW) platform Our signal detection & management platform, the Commonwealth Vigilance Workbench (CVW), spans the full spectrum of the signal management process to ensure no signals are missed and important signals are prioritized. Working with life science companies we drive progress to continue protecting lives.
2022
Board Member
Nov 2022
Founded in 2015, LXO Group is a pharmaceutical company operating a range of products generating annual sales of over 90 million euros and covering more than 80 countries. We are committed to meeting the needs of healthcare professionals and patients for our medicines, medical devices and cosmetics. Our growth is fuelled by the success of our brands, our international expansion and our strategy of external acquisitions. We are supported by a strong workforce, our own sales force and a network of partners and sales representatives who are ready to invest in the development of our products.
Show all 9 entries ↓
Investment activity
2022–2024 · 5 investments
202222023220241
Recent (last 2 years)Earlier